All News

MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

Links:

Richard Conway RichardPAConway ( View Tweet)
Krijbolder et al on MTX to prevent RA in clinically suspect arthralgia. No effect on arthritis free survival (80 vs 82%). Some delay in RA onset in high-risk group. But there was a sustained improvement in symptoms in MTX group @RheumNow #EULAR2022 OP0070 https://t.co/0CPIP51yQd https://t.co/kWNmw1YzrH

Links:

Richard Conway RichardPAConway ( View Tweet)
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

Links:

Richard Conway RichardPAConway ( View Tweet)
NORD-STAR TRIAL drug does better in ttmt naive eRA? 48wks CDAI remission ▶️ w/ ABA and CERTO PEG vs. MTX+ GCs while TCZ not stat ▶️. Is the difference clinically sufficient to recommend these in first intention over MTX ? not convinced 🧐 OP0058 #EULAR22 @rheumnow

Aurelie Najm AurelieRheumo ( View Tweet)

Damien et al on Whipple's Disease presenting as RMD. 73 cases (wow!) Treat Whipples, 93% remission, 94% off DMARD @RheumNow #EULAR2022 OP0066 https://t.co/XQnQq4RNcq

Links:

Richard Conway RichardPAConway ( View Tweet)

10 year study showed NSAIDs associated with slowing radiographic progression in axSpA patients. mSASSS progression numerically lower in COX2i pts compared to non-selective NSAIDs. @RheumNow #EULAR2022 #ABSTOP0021 https://t.co/dfz3rseikl
Robert B Chao, MD doctorRBC ( View Tweet)
Combination tx of NSAIDs and TNFi (celecoxib and golimumab) did not show significant superiority compared to TNFi alone in slowing radiographic progression for treatment of radiographic axSpA. There was a numerical reduction however. #EULAR2022 @RheumNow #ABSTOP0018 https://t.co/gUZAwd92dK
Robert B Chao, MD doctorRBC ( View Tweet)
@Rheumnow #EULAR2022 POS0240 ▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL). Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies. What would you start as a first JAKi?

Eric Dein ericdeinmd ( View Tweet)

ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

Eric Dein ericdeinmd ( View Tweet)

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex KDAO2011 ( View Tweet)
Conv3.jpg

EULAR 2022 Featured Industry Abstracts

d Jack Cush, MD

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Read Article
GCA temporal artery

Giant Cell Arteritis Growing More Lethal

d MedPage Today

Mortality rates among patients with giant cell arteritis (GCA) in Canada's Ontario province rose by 15% from 2000 to 2018, a new study found, even as the general population saw declines in overall mortality.

Read Article
PSS.scleroderma.arthritis.contractures

Immune Checkpoint Inhibitor Associated Arthritis

d Jack Cush, MD

Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

Read Article
xray-of-hands-1526780.jpg

Bridge Prednisone Use Fails to Improve Outcomes

d Jack Cush, MD

A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.

Read Article
RNL22 RA Best Management

RNL 2022: Rheumatoid Arthritis - Best Management

d Jack Cush, MD

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Read Article
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Read Article
cardiac2.jpg (keep)

Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease

d Jack Cush, MD

The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.

Read Article
child.guttate.psoriasis

Psoriasis and Nonalcoholic Fatty Liver Disease

d Jack Cush, MD

A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).

Read Article
coronavirus,COVID,Mask,red

Increasing Corticosteroid Use in Non-Hospitalized COVID-19

d Jack Cush, MD

JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.

Read Article
dementia,brain

Is Gout Protective Against Dementia?

d MedPage Today

People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.